Charles River Laboratories International (CRL) Scheduled to Post Quarterly Earnings on Wednesday

Charles River Laboratories International (NYSE:CRL) is scheduled to post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Charles River Laboratories International to post earnings of $2.39 per share for the quarter. Charles River Laboratories International has set its FY24 guidance at $10.90-11.40 EPS and its FY 2024 guidance at 10.900-11.400 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Trading Down 3.1 %

Shares of Charles River Laboratories International stock opened at $226.42 on Tuesday. Charles River Laboratories International has a 12-month low of $161.65 and a 12-month high of $275.00. The company has a market cap of $11.66 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 2.32 and a beta of 1.38. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The company’s 50-day moving average price is $215.25 and its 200-day moving average price is $231.58.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating on the stock in a report on Wednesday, July 10th. The Goldman Sachs Group started coverage on shares of Charles River Laboratories International in a research report on Thursday, June 6th. They issued a “buy” rating and a $290.00 price objective on the stock. TD Cowen decreased their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research report on Monday, May 13th. Argus restated a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Finally, StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $252.29.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).